3 citations
,
February 2005 in “Lung Cancer” The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.
July 2024 in “Journal of Investigative Dermatology” Recombinant human TSG-6 speeds up wound healing in diabetic mice.
January 2023 in “RSC Advances” The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
January 2016 in “프로그램북(구 초록집)” The growth factor cocktail with FGF9 significantly increased hair density and diameter in patients with androgenetic alopecia.
June 2026 in “Current Oncology Reports” Sacituzumab Tirumotecan shows promise in treating gynecologic cancers with manageable side effects.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
1 citations
,
January 2003 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not accessible or understandable.
1 citations
,
May 2021 in “Annals of the rheumatic diseases” Tofacitinib is a promising treatment for children with rheumatic diseases.
3 citations
,
June 1993 in “Hair transplant forum international” The document's conclusion cannot be provided because the content is not available to parse.
1 citations
,
September 1994 in “Hair transplant forum international” The document's content cannot be understood or processed.
1 citations
,
May 2001 in “Hair transplant forum international” The document's conclusion cannot be summarized because the content is not accessible or understandable.
February 2023 in “Materials today bio” The treatment effectively promotes hair regrowth in androgenetic alopecia without causing skin irritation.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” ONCO-NK-TRANSITION-GM1 is a low-cost, effective cancer treatment with a high cure rate and no severe side effects.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” ONCO-NK-TRANSITION-GM1 is a low-cost, effective cancer treatment with a high cure rate and no severe side effects.
8 citations
,
March 2015 in “International Journal of Oncology” Tsc2-deficient stem cells can help understand and treat TSC-related tumors.
November 2017 in “Hair transplant forum international” I'm sorry, but I can't provide a summary without content from the document.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
January 2000 in “Dermatology” 4 citations
,
July 2023 in “Frontiers in Microbiology” HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.
1 citations
,
January 1996 in “Hair transplant forum international” The document's conclusion cannot be provided because the document is not available or cannot be parsed.
April 2012 in “Neuropediatrics” Trichothiodystrophy is a rare genetic disorder causing hair issues and sometimes linked to DNA repair defects.
August 2024 in “Veterinary Dermatology” Topical ceramide treatment partially improves the skin condition in Jack Russell Terriers with a genetic skin disorder.
20 citations
,
September 2015 in “Protein expression and purification” Scientists made safflower seeds produce a human growth factor that could help with hair growth and wound healing.
May 2022 in “Reactions Weekly”
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
January 2023 in “Turk Dermatoloji Dergisi” Injecting a cell suspension from hair follicles increased hair density in a balding patient.
March 2026 in “Voprosy dermatologii i venerologii/Dermatologiâ ža̋ne veneralogiâ ma̋selelerì” Early diagnosis, genetic testing, and personalized care are essential for managing tuberous sclerosis.
July 2026 in “Chemical Engineering Journal”
November 1998 in “Hair transplant forum international” The document's conclusion cannot be provided because the content is not accessible.